About
Pyrojas develops personalized autologous whole tumor cell vaccines engineered from a patient's own cancer cells to activate a broad and durable immune response against heterogeneous cancer antigens.
Explore Pyrojas's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.